Study record · Sermorelin
Nightly GHRH(1-29) in healthy older men
Nocturnal GH increased, but IGF-I did not significantly increase; 2 of 6 strength/performance measures improved while DEXA body composition did not change.
Key result
Nocturnal GH increased, but IGF-I did not significantly increase; 2 of 6 strength/performance measures improved while DEXA body composition did not change.
Study details
Study designRandomized placebo-controlled clinical physiology study
PopulationHealthy non-obese men aged 64-76 with low IGF-I
Sample size11
RouteSubcutaneous
Regimen / exposure2 mg GHRH(1-29) nightly
Duration6 weeks
ComparatorPlacebo
Primary endpoint / questionNocturnal GH, IGF-I, body composition and physical performance
Safety resultNo significant adverse effects reported in the abstract.
Key limitationsVery small study; native GHRH(1-29), not Modified GRF; short duration and surrogate/functional endpoints.
Registry / identifierPMID 9005976